{
  "symbol": "TMDX",
  "company_name": "Transmedics Group Inc",
  "ir_website": "https://investors.transmedics.com/",
  "structured_data": [
    {
      "section_name": "News Releases",
      "links": [
        {
          "title": "TransMedics to Host Investor & Analyst Day on December 10, 2024",
          "url": "https://investors.transmedics.com/news-releases/news-release-details/transmedics-host-investor-analyst-day-december-10-2024",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  News Release \n\n# \n\nTransMedics to Host Investor & Analyst Day on December 10, 2024\n\nNov 26, 2024 at 4:05 PM EST\n\n[PDF Version](/node/10236/pdf)\n\nANDOVER, Mass., Nov. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it will host an Investor & Analyst Day in New York City on Tuesday, December 10, 2024, at 10:00 AM ET.\n\n[ ![\\(PRNewsfoto/TransMedics, Inc.\\)](https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg) ](https://mma.prnewswire.com/media/676128/TransMedics_Logo.html)\n\nWaleed Hassanein, MD., President and Chief Executive Officer, and members of the leadership team will present an overview of TransMedics' growth strategy, clinical pipeline, and operations. \n\nA live and archived webcast of presentations and Q&A sessions will be available on the \"Investors\" section of the TransMedics website at [https://investors.transmedics.com](https://c212.net/c/link/?t=0&l=en&o=4312659-1&h=3950007216&u=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2F___https%3A%2Finvestors.transmedics.com___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5MzI5NTZlZDg3YTU1ZGRiZmJlMGYxMzViODliODBmNTo2OjI4MjM6MWNlNjI3NmZhZTdiOTZmOTYzZDVlYWFkOGZkMGExNjNiNzA3YTYyZTIwNzY0NDQ1N2YxNzUwODA4YTE5MTU4NzpoOlQ6Rg&a=https%3A%2F%2Finvestors.transmedics.com). Please note management will only take questions from the live audience during the question-and-answer session following the formal presentations.\n\nIn-person attendance at the event requires advanced registration. Please email Laine Morgan at laine@gilmartinir.com by December 4, 2024, for further information. \n\n**About TransMedics Group, Inc. **TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.\n\n**Investor Contact:** Brian JohnstonLaine Morgan332-895-3222Investors@transmedics.com\n\n![Cision](https://c212.net/c/img/favicon.png?sn=NE66847&sd=2024-11-26) View original content to download multimedia:<https://www.prnewswire.com/news-releases/transmedics-to-host-investor--analyst-day-on-december-10-2024-302316931.html>\n\nSOURCE TransMedics Group, Inc.\n"
        },
        {
          "title": "TransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://investors.transmedics.com/news-releases/news-release-details/transmedics-participate-piper-sandler-36th-annual-healthcare",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  News Release \n\n# \n\nTransMedics to Participate in the Piper Sandler 36th Annual Healthcare Conference\n\nNov 19, 2024 at 4:05 PM EST\n\n[PDF Version](/node/10231/pdf)\n\nANDOVER, Mass., Nov. 19, 2024 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024, at 4:00 p.m. Eastern Time.\n\n[ ![\\(PRNewsfoto/TransMedics, Inc.\\)](https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg) ](https://mma.prnewswire.com/media/676128/TransMedics_Logo.html)\n\n**Event: Piper Sandler 36 th Annual Healthcare Conference**Date: Tuesday, December 3, 2024Time: 4:00 p.m. ET\n\nA live and archived webcast of the fireside chat will be available on the \"Investors\" section of the TransMedics website at [https://investors.transmedics.com](https://c212.net/c/link/?t=0&l=en&o=4306929-1&h=3625738441&u=https%3A%2F%2Finvestors.transmedics.com%2F&a=https%3A%2F%2Finvestors.transmedics.com). The Company's standard investor presentation is also available through this link.\n\n**About TransMedics Group, Inc.** TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.\n\n**Investor Contact:** Brian Johnston332-895-3222Investors@transmedics.com\n\n![Cision](https://c212.net/c/img/favicon.png?sn=NE60951&sd=2024-11-19) View original content to download multimedia:<https://www.prnewswire.com/news-releases/transmedics-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302310521.html>\n\nSOURCE TransMedics Group, Inc.\n"
        },
        {
          "title": "TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)",
          "url": "https://investors.transmedics.com/news-releases/news-release-details/transmedics-reports-inducement-grants-under-nasdaq-listing-21",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  News Release \n\n# \n\nTransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\n\nOct 29, 2024 at 4:05 PM EDT\n\n[PDF Version](/node/10191/pdf)\n\nANDOVER, Mass., Oct. 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. (\"TransMedics\") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 23, 2024, TransMedics granted non-qualified stock options to purchase an aggregate of 2,969 shares of its common stock and an aggregate of 1,937 restricted stock units to 6 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.\n\n[ ![\\(PRNewsfoto/TransMedics, Inc.\\)](https://mma.prnewswire.com/media/676128/TransMedics_Logo.jpg) ](https://mma.prnewswire.com/media/676128/TransMedics_Logo.html)\n\nTransMedics granted non-qualified stock options to purchase 2,969 shares of TransMedics' common stock and 1,937 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $118.66, the closing price of the common stock on the Nasdaq Global Market on October 23, 2024. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the Company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.\n\n**About TransMedics Group, Inc. **TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.\n\n**Investor Contact:** Brian Johnston332-895-3222Investors@transmedics.com\n\n![Cision](https://c212.net/c/img/favicon.png?sn=NE43011&sd=2024-10-29) View original content to download multimedia:<https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302290516.html>\n\nSOURCE TransMedics Group, Inc.\n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://investors.transmedics.com/events/event-details/piper-sandler-36th-annual-healthcare-conference",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Event Details \n\nDec 3, 2024 at 4:00 PM EST\n\n## Piper Sandler 36th Annual Healthcare Conference\n\n[Add to Outlook](/node/10226/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=TransMedics - Piper Sandler 36th Annual Healthcare Conference&dates=20241203T210000Z/20241203T210000Z&details=Event Details: http://investors.transmedics.com/events/event-details/piper-sandler-36th-annual-healthcare-conference%0A%0AWebcast: https://event.webcasts.com/starthere.jsp?ei=1699126&tp_key=25a94798e1&location=&trp=false&sprop=&sprop=name:)\n\n[Click here for Webcast](https://event.webcasts.com/starthere.jsp?ei=1699126&tp_key=25a94798e1)\n"
        },
        {
          "title": "TransMedics Q3 2024 Earnings Conference Call",
          "url": "https://investors.transmedics.com/events/event-details/transmedics-q3-2024-earnings-conference-call",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Event Details \n\nOct 28, 2024 at 4:30 PM EDT\n\n## TransMedics Q3 2024 Earnings Conference Call\n\n[Click here for Webcast](https://event.choruscall.com/mediaframe/webcast.html?webcastid=kZbR32wT)\n"
        },
        {
          "title": "Morgan Stanley 22nd Annual Global Healthcare Conference",
          "url": "https://investors.transmedics.com/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Event Details \n\nSep 4, 2024 at 1:05 PM EDT\n\n## Morgan Stanley 22nd Annual Global Healthcare Conference\n\n[Click here for Webcast](https://event.webcasts.com/starthere.jsp?ei=1685872&tp_key=776cf76a3f&tp_special=8)\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://investors.transmedics.com/investor-faqs",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Investor FAQs \n\n#  Investor FAQs \n\n[Show All](#)\n\nWhere is TransMedics’ corporate headquarters?\n\nThe TransMedics corporate headquarters is located at 200 Minuteman Road, Suite 302, Andover, MA 01810\n\nWhere is TransMedics incorporated?\n\nTransMedics Group, Inc. is incorporated in Massachusetts\n\nOn what stock exchange are TransMedics’ shares traded, and what is the ticker symbol?\n\nThe TransMedics ticker is TMDX and it is traded on the NASDAQ exchange.\n\nDoes TransMedics have a direct stock purchase plan?\n\nTransMedics does not currently have a direct stock purchase plan.\n\nWhere can I find all of TransMedics’ SEC filings? Where can I download and view quarterly and annual reports?\n\nQuarterly and annual reports, as well as other SEC filings, can be accessed on the [SEC Filings](/sec-filings) portion of our Investor Relations website or directly from the SEC at [www.sec.gov](https://www.sec.gov).\n\nWhat is TransMedics’ fiscal year? \n\nOur fiscal year ends on the last Saturday in December, and we report fiscal years using a 52/53-week convention. Under this convention, certain fiscal years contain 53 weeks. Each fiscal year is typically composed of four 13-week fiscal quarters, but in years with 53 weeks, the fourth quarter is a 14-week period.\n\nDoes TransMedics pay dividends?\n\nTransMedics has not paid dividends.\n\nWho is TransMedics’ auditor?\n\nTransMedics’ is audited by PricewaterhouseCoopers (PWC).\n\nWho is TransMedics’ transfer agent?\n\nTransMedics uses American Stock Transfer & Trust Company. (718) 921-8300 or (800) 937-5449 (American Stock Transfer & Trust Company Call Center is open Monday through Friday, 8AM to 8PM ET); Mail: 6201 15th Avenue, Brooklyn, NY 11219 [www.astfinancial.com](https://www.astfinancial.com).\n\nWho is TransMedics’ legal counsel?\n\nTransMedics’ legal counsel is Ropes & Gray LLP.\n\nWhere can I find out more about TransMedics?\n\nMore information can be found at [www.transmedics.com](https://www.transmedics.com).\n\nWhere can I get the latest corporate news releases and financial reports?\n\nAll corporate news releases and financial information can be found at [on the Investor Relations website](/sec-filings).\n\nWho makes up the TransMedics’ Executive Management team and Board of Directors?\n\nThis information can be found on the TransMedics website, [www.transmedics.com/leadership](https://www.transmedics.com/leadership).\n\nWhom should I contact regarding investor inquiries?\n\nInvestor inquiries can be directed to investors@transmedics.com.\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.transmedics.com/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Email Alerts \n\n#  Email Alerts \n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nEvent  \nNews  \nWeekly Summary  \n  \nEmail\n\nLeave this field blank\n"
        },
        {
          "title": "Contact IR",
          "url": "https://investors.transmedics.com/contact-ir",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Contact IR \n\n#  Contact IR \n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n"
        }
      ]
    },
    {
      "section_name": "Financial Information",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.transmedics.com/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  SEC Filings \n\n#  SEC Filings \n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -2024202320222021202020192018\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | View  \n---|---|---|---  \nNov, 13 2024 | [4](/sec-filings/sec-filing/4/0000950170-24-126397) | Statement of changes in beneficial ownership of securities |  [0000950170-24-126397.pdf](/static-files/6fd9bc91-c163-4fb2-ba0a-1bfb8228c08c) [0000950170-24-126397.rtf](/static-files/ae4e6f11-3989-4564-a890-8e5cc16bd48c) [0000950170-24-126397.xls](/static-files/ece2599e-ec6f-4969-aa08-9d5c62700458) [View HTML](/node/10221/html)  \nNov, 7 2024 | [4](/sec-filings/sec-filing/4/0000950170-24-123425) | Statement of changes in beneficial ownership of securities |  [0000950170-24-123425.pdf](/static-files/a43947c9-64f5-4508-bdf1-b5feb74a8700) [0000950170-24-123425.rtf](/static-files/4b23923f-b31d-4548-b433-2a72c1bede67) [0000950170-24-123425.xls](/static-files/38a50f59-80f1-4806-bdbe-e99b028de514) [View HTML](/node/10216/html)  \nNov, 5 2024 | [144](/sec-filings/sec-filing/144/0001950047-24-008096) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  [0001950047-24-008096.pdf](/static-files/32f7b94a-530a-487a-8851-6dd3ce87182d) [0001950047-24-008096.rtf](/static-files/ce40c4a8-11b0-4bed-bbcb-6934b4088087) [View HTML](/node/10206/html)  \nNov, 5 2024 | [4](/sec-filings/sec-filing/4/0000950170-24-121525) | Statement of changes in beneficial ownership of securities |  [0000950170-24-121525.pdf](/static-files/556340b3-1e33-489d-8bf3-f2b422d8eb40) [0000950170-24-121525.rtf](/static-files/f2e2de16-d723-4910-8c26-ce48036481a7) [0000950170-24-121525.xls](/static-files/e320a875-d38a-4c5e-9871-1e8df36b8149) [View HTML](/node/10211/html)  \nNov, 1 2024 | [144](/sec-filings/sec-filing/144/0001968582-24-000954) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  [0001968582-24-000954.pdf](/static-files/e5c6a1d3-5925-4f95-ad05-002d4d4086d2) [0001968582-24-000954.rtf](/static-files/9826e895-4a87-46c0-84aa-9971a793b3ec) [0001968582-24-000954.xls](/static-files/d9845438-47c8-408b-80ab-9b0858e47fa0) [View HTML](/node/10201/html)  \nOct, 29 2024 | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-118260) | Quarterly report which provides a continuing view of a company's financial position |  [0000950170-24-118260.pdf](/static-files/f59e18a0-4c81-444d-9406-518b782554e0) [0000950170-24-118260.rtf](/static-files/d7790502-372c-4f21-9ebe-d904336d2021) [0000950170-24-118260.xls](/static-files/52c2ad06-f3c9-4a0c-8f7b-4cc75df91abb) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-118260) [View HTML](/node/10196/html)  \nOct, 28 2024 | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-117727) | Report of unscheduled material events or corporate event |  [0000950170-24-117727.pdf](/static-files/aa50616e-3074-428c-9ddd-bf8e1640d77f) [0000950170-24-117727.rtf](/static-files/a0760e35-f2c4-4f93-9557-f1dfcec93a95) [0000950170-24-117727.xls](/static-files/c200790d-c1eb-46c6-92a5-f26e3ecc601b) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-117727) [View HTML](/node/10186/html)  \nOct, 17 2024 | [4](/sec-filings/sec-filing/4/0000950170-24-115332) | Statement of changes in beneficial ownership of securities |  [0000950170-24-115332.pdf](/static-files/920cf12c-335c-4525-84f0-7f67af12fa79) [0000950170-24-115332.rtf](/static-files/82d5a853-b1b7-4fab-bf1d-152b37131fdb) [0000950170-24-115332.xls](/static-files/d844a6f8-3032-4539-b525-34be27a9def2) [View HTML](/node/10176/html)  \nOct, 7 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000315066-24-002033) | An amendment to the SC 13G filing |  [0000315066-24-002033.pdf](/static-files/46e2661c-071e-4302-a988-d398ca6c8b1e) [0000315066-24-002033.rtf](/static-files/130b7ffa-7d60-45d5-8bc8-d70f0aab1343) [View HTML](/node/10156/html)  \nOct, 7 2024 | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0002012383-24-000118) | An amendment to the SC 13G filing |  [0002012383-24-000118.pdf](/static-files/12787e01-21a5-4fe6-a6d1-101cc44f9b82) [0002012383-24-000118.rtf](/static-files/18d0ccd4-a8b7-4082-9c0c-039458083254) [View HTML](/node/10161/html)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Governance Highlights",
          "url": "https://investors.transmedics.com/governance-highlights",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Governance Highlights \n\n#  Governance Highlights \n\n##  Governance Documents \n\n[Conflict Minerals Statement](/static-files/2d13abcb-f306-4270-865d-0ad7d8423505)\n\n75.33 KB\n\n[Whistleblower Policy](/static-files/a1130ec2-6000-41d4-a4e1-aca2dea35fb2)\n\n77.13 KB\n\n[Code of Business Conduct & Ethics](/static-files/e296e9a2-6330-4640-b2df-a47fcdb923e7)\n\n343.46 KB\n\n[Corporate Governance Guidelines](/static-files/6b0f4499-9377-4dd0-9e6c-03076d6a85d8)\n\n97.83 KB\n\n##  Committee Charters \n\n[Nominating and Corporate Governance Committee Charter](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)\n\n[Audit Committee Charter](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4)\n\n[Compensation Committee Charter](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183)\n"
        },
        {
          "title": "Management Team",
          "url": "https://www.transmedics.com/leadership/",
          "content": "[ ![Transmedics](https://www.transmedics.com/wp-content/uploads/2019/03/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * Patients & Families\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS™ Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS™ Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS™ Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS™ Location](https://www.transmedics.com/locate-ocs/)\n  * Transplant Professionals\n    * [National OCS Program](https://www.transmedics.com/national-ocs-program/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS™ Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS™ Lung Solution](https://www.transmedics.com/lung-solution/)\n    * [OCS™ Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS™ Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * Our Company\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Latest News](https://www.transmedics.com/in-the-news/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](https://investors.transmedics.com)\n  * [National OCS Program](https://www.transmedics.com/national-ocs-program/)\n\n\n\n# Meet theTransMedics Team\n\nExperience and Innovation For the Future of Organ Preservation\n\n![](https://www.transmedics.com/wp-content/uploads/2024/07/TMDX_Leadership_team_0724.jpg)\n\nThe TransMedics leadership team brings a wealth of experience in the fields of organ transplantation, clinical research, medical devices, and many others to our goal of improving the lives of transplant patients and their families around the world.\n\n![Waleed Hassanein, M.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_WaleedH_648x648.jpg)\n\n#### Waleed Hassanein, M.D.\n\n##### TransMedics Founder, President and CEO\n\n[](javascript:void\\(0\\))\n\nDr. Waleed Hassanein founded TransMedics in 1998 to revolutionize organ transplant therapy for the treatment of end-stage lung, heart, and liver failure. Dr. Hassanein’s pioneering clinical research led to the development of an entirely new living organ preservation field for transplantation. Human organs could now be kept alive and functioning (heart beating, lung breathing, liver producing bile, etc.) outside of the human body in TransMedics’ revolutionary portable Organ Care System (OCS™) technology. Under his leadership, TransMedics has established itself as the global leader in living organ preservation and the OCS™ technology is becoming the new standard of care for solid organ transplantation. Dr. Hassanein was named as one of the top 50 Global Thinkers in Healthcare by Foreign Policy Magazine in 2015. He was the awardee of the Tribeca Disruptive Innovators Award in 2018 and was a finalist for the European Patent Office Inventor Award in 2017. Dr. Hassanein is a frequent guest speaker in national and international meetings on the future of organ preservation for transplantation. Dr. Hassanein earned his M.D. from Georgetown University School of Medicine. He completed two years of general surgery training at Georgetown University Medical Center. He then completed a three-year cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women’s Hospital in Boston. His research on  _ex-vivo_ heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery in 1998.\n\n![Stephen Gordon, MBA](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_StephenG_648x648.jpg)\n\n#### Stephen Gordon, MBA\n\n##### Chief Financial Officer\n\n[](javascript:void\\(0\\))\n\nStephen Gordon joined TransMedics in March of 2015 and leads our finance and accounting team. He has over 20 years of experience leading financial organizations within high technology and medical device companies. During this time his areas of focus have been strategic planning, M&A integration, financial planning and analysis, and improvement in the presentation of quantitative information. Prior to joining TransMedics, Mr. Gordon was the Vice President, Financial Planning & Analysis at Analogic Corporation, a medical device and security technology company. Before joining Analogic, Mr. Gordon held various financial leadership positions at Hologic, Cytyc, Maxtor and Hewlett-Packard. Mr. Gordon earned a Bachelor’s degree in Finance and Accounting from The Wharton School at The University of Pennsylvania, and an MBA from Boston University.\n\n![Tamer Khayal, M.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_TamerK_648x648.jpg)\n\n#### Tamer Khayal, M.D.\n\n##### Chief Commercial Officer\n\n[](javascript:void\\(0\\))\n\nDr. Khayal joined TransMedics in 2001. Over the past 18 years Dr. Tamer Khayal assumed growing responsibilities to the current role of Chief Commercial Officer in January 2018. From 2007-2018 he was the Chief Medical Officer leading TransMedics’ global effort of building the clinical evidence, reimbursement initiatives and use model integration programs to support the PMA approvals and global commercial adoption of the Organ Care (OCS™) technology for lung, heart and liver transplantation. His patient focused approached to commercial rollout, made Dr. Khayal gain the trust and respect of the OCS™ users world-wide. Prior to joining TransMedics, Dr. Khayal served for six years as the Director of Medical Affairs for Zentiva Middle East, a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s ME&A operations. Dr. Khayal received his MD degree from Cairo University School of Medicine and a General Certificate of Education from the University of London, England.\n\n![Anil Ranganath](https://www.transmedics.com/wp-content/uploads/2023/08/AnilR-Headshot.png)\n\n#### Anil Ranganath\n\n##### Senior Vice President, General Counsel & Corporate Secretary\n\n[](javascript:void\\(0\\))\n\nAnil Ranganath joins TransMedics with over 15 years of experience in the life sciences and biotechnology tools industries. Prior to joining TransMedics, Mr. Ranganath served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters’ strategic, tactical, and operational plans. He began his legal career as an Associate at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a Bachelor’s degree in Computer Science from Worcester Polytechnic Institute.\n\n![Nick Corcoran](https://www.transmedics.com/wp-content/uploads/2023/03/Nick_03092023.jpg)\n\n#### Nick Corcoran\n\n##### Senior Vice President of Supply Chain & Operations\n\n[](javascript:void\\(0\\))\n\nNick Corcoran joins TransMedics with over 20 years of experience in global supply chain and commercial operations. Prior to joining TransMedics, Mr. Corcoran served multiple roles of increasing responsibility at Stryker Corporation. Most recently, Mr. Corcoran served as Vice President of Division Operations for Stryker Joint Replacement, managing the division’s entire supply chain, including internal manufacturing sites and external supply partners. Earlier in his career at Stryker, Mr. Corcoran served as Vice President of Division and Commercial Operations for the Spine Division, Senior Director of Division Operations, and Director of Global Sourcing. He also held a variety of Supply Chain and Operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran holds a bachelor’s degree in Finance and Economics from South East Technological University and a Master’s of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.\n\n![Miriam Provost, Ph.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_MiriamP_648x648.jpg)\n\n#### Miriam Provost, Ph.D.\n\n##### Vice President of Global Regulatory Affairs\n\n[](javascript:void\\(0\\))\n\nMiriam Provost has over 24 years of experience in Medical Device Regulatory Affairs, including 13 years at the Food and Drug Administration. Prior to joining TransMedics, Dr. Provost was an internationally recognized expert in Regulatory Affairs and provided strategic guidance and tactical support for large and small medical device companies as medical device regulatory consultant. Her expertise stems from 13 years as a reviewer and manager at the Food and Drug Administration where she served in a variety of roles across the Agency, gaining broad knowledge and familiarity with all matters related to FDA policies, procedures and decision-making. Dr. Provost earned a Bachelor’s degree in Chemical Engineering from the University of Dayton and M.S. and Ph.D. degrees in Chemical Engineering from the University of Pennsylvania.\n\n![Mark Anderson](https://www.transmedics.com/wp-content/uploads/2020/02/Mark_2785_1.jpg)\n\n#### Mark Anderson\n\n##### Vice President, Product Development\n\n[](javascript:void\\(0\\))\n\nMark Anderson joined TransMedics in March of 2006. With over 15 years of complex product development and engineering management expertise, Mr. Anderson has a proven record of bringing innovative Class II and Class III medical products to market, including organ perfusion and heart assist devices. Prior to joining TransMedics, Mr. Anderson served as R&D Manager of Software and Electrical Engineering for Teleflex Inc., where he led technical teams developing the next-generation intra-aortic balloon pump. He also held electrical and systems engineering roles developing submarine sonar systems for the Naval Undersea Warfare Center. Mr. Anderson earned a Bachelor’s degree in Electrical Engineering with a minor in Computer Science from Worcester Polytechnic Institute.\n\n![Laura Damme, BSN, MPH](https://www.transmedics.com/wp-content/uploads/2020/02/Laura_Damme.jpg)\n\n#### Laura Damme, BSN, MPH\n\n##### Vice President, Clinical Affairs\n\n[](javascript:void\\(0\\))\n\nLaura joins TransMedics with over 20 years of experience leading clinical affairs teams in the conduct and execution of medical device clinical studies which have resulted in successful approvals. Before joining TransMedics, Laura served as Director of Clinical Studies at Thoratec Corporation/Abbott, specializing in their Mechanical Circulatory Support business. Laura holds a Master of Public Health from the University of Michigan and received her nursing degree from Grand Valley State University.\n\n## TransMedics Board of Directors and Observers\n\n  * James R. Tobin _Chairman of TransMedics Board_\n  * Edward M. Basile\n  * Thomas J. Gunderson\n  * Merilee Raines\n\n\n\n  * Waleed Hassanein, MD _President and Chief Executive Officer_\n  * Edwin M. Kania, Jr.\n  * David Weill, M.D.\n  * Stephanie Lovell\n\n\n\n[WordPress Lightbox](http://www.wonderplugin.com/wordpress-lightbox/ \"WordPress Lightbox\")\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://www.transmedics.com/leadership#board-directors-list",
          "content": "[ ![Transmedics](https://www.transmedics.com/wp-content/uploads/2019/03/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * Patients & Families\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS™ Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS™ Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS™ Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS™ Location](https://www.transmedics.com/locate-ocs/)\n  * Transplant Professionals\n    * [National OCS Program](https://www.transmedics.com/national-ocs-program/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS™ Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS™ Lung Solution](https://www.transmedics.com/lung-solution/)\n    * [OCS™ Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS™ Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * Our Company\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Latest News](https://www.transmedics.com/in-the-news/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](https://investors.transmedics.com)\n  * [National OCS Program](https://www.transmedics.com/national-ocs-program/)\n\n\n\n# Meet theTransMedics Team\n\nExperience and Innovation For the Future of Organ Preservation\n\n![](https://www.transmedics.com/wp-content/uploads/2024/07/TMDX_Leadership_team_0724.jpg)\n\nThe TransMedics leadership team brings a wealth of experience in the fields of organ transplantation, clinical research, medical devices, and many others to our goal of improving the lives of transplant patients and their families around the world.\n\n![Waleed Hassanein, M.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_WaleedH_648x648.jpg)\n\n#### Waleed Hassanein, M.D.\n\n##### TransMedics Founder, President and CEO\n\n[](javascript:void\\(0\\))\n\nDr. Waleed Hassanein founded TransMedics in 1998 to revolutionize organ transplant therapy for the treatment of end-stage lung, heart, and liver failure. Dr. Hassanein’s pioneering clinical research led to the development of an entirely new living organ preservation field for transplantation. Human organs could now be kept alive and functioning (heart beating, lung breathing, liver producing bile, etc.) outside of the human body in TransMedics’ revolutionary portable Organ Care System (OCS™) technology. Under his leadership, TransMedics has established itself as the global leader in living organ preservation and the OCS™ technology is becoming the new standard of care for solid organ transplantation. Dr. Hassanein was named as one of the top 50 Global Thinkers in Healthcare by Foreign Policy Magazine in 2015. He was the awardee of the Tribeca Disruptive Innovators Award in 2018 and was a finalist for the European Patent Office Inventor Award in 2017. Dr. Hassanein is a frequent guest speaker in national and international meetings on the future of organ preservation for transplantation. Dr. Hassanein earned his M.D. from Georgetown University School of Medicine. He completed two years of general surgery training at Georgetown University Medical Center. He then completed a three-year cardiac surgery research fellowship at the West Roxbury VA Medical Center and Brigham and Women’s Hospital in Boston. His research on  _ex-vivo_ heart perfusion for transplantation was recognized by the American Association for Thoracic Surgery in 1998.\n\n![Stephen Gordon, MBA](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_StephenG_648x648.jpg)\n\n#### Stephen Gordon, MBA\n\n##### Chief Financial Officer\n\n[](javascript:void\\(0\\))\n\nStephen Gordon joined TransMedics in March of 2015 and leads our finance and accounting team. He has over 20 years of experience leading financial organizations within high technology and medical device companies. During this time his areas of focus have been strategic planning, M&A integration, financial planning and analysis, and improvement in the presentation of quantitative information. Prior to joining TransMedics, Mr. Gordon was the Vice President, Financial Planning & Analysis at Analogic Corporation, a medical device and security technology company. Before joining Analogic, Mr. Gordon held various financial leadership positions at Hologic, Cytyc, Maxtor and Hewlett-Packard. Mr. Gordon earned a Bachelor’s degree in Finance and Accounting from The Wharton School at The University of Pennsylvania, and an MBA from Boston University.\n\n![Tamer Khayal, M.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_TamerK_648x648.jpg)\n\n#### Tamer Khayal, M.D.\n\n##### Chief Commercial Officer\n\n[](javascript:void\\(0\\))\n\nDr. Khayal joined TransMedics in 2001. Over the past 18 years Dr. Tamer Khayal assumed growing responsibilities to the current role of Chief Commercial Officer in January 2018. From 2007-2018 he was the Chief Medical Officer leading TransMedics’ global effort of building the clinical evidence, reimbursement initiatives and use model integration programs to support the PMA approvals and global commercial adoption of the Organ Care (OCS™) technology for lung, heart and liver transplantation. His patient focused approached to commercial rollout, made Dr. Khayal gain the trust and respect of the OCS™ users world-wide. Prior to joining TransMedics, Dr. Khayal served for six years as the Director of Medical Affairs for Zentiva Middle East, a pharmaceutical company, where he led clinical research, regulatory filings and clinical sales training for the company’s ME&A operations. Dr. Khayal received his MD degree from Cairo University School of Medicine and a General Certificate of Education from the University of London, England.\n\n![Anil Ranganath](https://www.transmedics.com/wp-content/uploads/2023/08/AnilR-Headshot.png)\n\n#### Anil Ranganath\n\n##### Senior Vice President, General Counsel & Corporate Secretary\n\n[](javascript:void\\(0\\))\n\nAnil Ranganath joins TransMedics with over 15 years of experience in the life sciences and biotechnology tools industries. Prior to joining TransMedics, Mr. Ranganath served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters’ strategic, tactical, and operational plans. He began his legal career as an Associate at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a Bachelor’s degree in Computer Science from Worcester Polytechnic Institute.\n\n![Nick Corcoran](https://www.transmedics.com/wp-content/uploads/2023/03/Nick_03092023.jpg)\n\n#### Nick Corcoran\n\n##### Senior Vice President of Supply Chain & Operations\n\n[](javascript:void\\(0\\))\n\nNick Corcoran joins TransMedics with over 20 years of experience in global supply chain and commercial operations. Prior to joining TransMedics, Mr. Corcoran served multiple roles of increasing responsibility at Stryker Corporation. Most recently, Mr. Corcoran served as Vice President of Division Operations for Stryker Joint Replacement, managing the division’s entire supply chain, including internal manufacturing sites and external supply partners. Earlier in his career at Stryker, Mr. Corcoran served as Vice President of Division and Commercial Operations for the Spine Division, Senior Director of Division Operations, and Director of Global Sourcing. He also held a variety of Supply Chain and Operations roles at Waters Corporation and Intel Corporation. Mr. Corcoran holds a bachelor’s degree in Finance and Economics from South East Technological University and a Master’s of Business in Supply Chain Management from The Smurfit School of Business, University College Dublin.\n\n![Miriam Provost, Ph.D.](https://www.transmedics.com/wp-content/uploads/2019/03/3.1_MiriamP_648x648.jpg)\n\n#### Miriam Provost, Ph.D.\n\n##### Vice President of Global Regulatory Affairs\n\n[](javascript:void\\(0\\))\n\nMiriam Provost has over 24 years of experience in Medical Device Regulatory Affairs, including 13 years at the Food and Drug Administration. Prior to joining TransMedics, Dr. Provost was an internationally recognized expert in Regulatory Affairs and provided strategic guidance and tactical support for large and small medical device companies as medical device regulatory consultant. Her expertise stems from 13 years as a reviewer and manager at the Food and Drug Administration where she served in a variety of roles across the Agency, gaining broad knowledge and familiarity with all matters related to FDA policies, procedures and decision-making. Dr. Provost earned a Bachelor’s degree in Chemical Engineering from the University of Dayton and M.S. and Ph.D. degrees in Chemical Engineering from the University of Pennsylvania.\n\n![Mark Anderson](https://www.transmedics.com/wp-content/uploads/2020/02/Mark_2785_1.jpg)\n\n#### Mark Anderson\n\n##### Vice President, Product Development\n\n[](javascript:void\\(0\\))\n\nMark Anderson joined TransMedics in March of 2006. With over 15 years of complex product development and engineering management expertise, Mr. Anderson has a proven record of bringing innovative Class II and Class III medical products to market, including organ perfusion and heart assist devices. Prior to joining TransMedics, Mr. Anderson served as R&D Manager of Software and Electrical Engineering for Teleflex Inc., where he led technical teams developing the next-generation intra-aortic balloon pump. He also held electrical and systems engineering roles developing submarine sonar systems for the Naval Undersea Warfare Center. Mr. Anderson earned a Bachelor’s degree in Electrical Engineering with a minor in Computer Science from Worcester Polytechnic Institute.\n\n![Laura Damme, BSN, MPH](https://www.transmedics.com/wp-content/uploads/2020/02/Laura_Damme.jpg)\n\n#### Laura Damme, BSN, MPH\n\n##### Vice President, Clinical Affairs\n\n[](javascript:void\\(0\\))\n\nLaura joins TransMedics with over 20 years of experience leading clinical affairs teams in the conduct and execution of medical device clinical studies which have resulted in successful approvals. Before joining TransMedics, Laura served as Director of Clinical Studies at Thoratec Corporation/Abbott, specializing in their Mechanical Circulatory Support business. Laura holds a Master of Public Health from the University of Michigan and received her nursing degree from Grand Valley State University.\n\n## TransMedics Board of Directors and Observers\n\n  * James R. Tobin _Chairman of TransMedics Board_\n  * Edward M. Basile\n  * Thomas J. Gunderson\n  * Merilee Raines\n\n\n\n  * Waleed Hassanein, MD _President and Chief Executive Officer_\n  * Edwin M. Kania, Jr.\n  * David Weill, M.D.\n  * Stephanie Lovell\n\n\n\n[WordPress Lightbox](http://www.wonderplugin.com/wordpress-lightbox/ \"WordPress Lightbox\")\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://investors.transmedics.com/committee-composition",
          "content": "Cookie Policy\n\nThis website uses cookies to ensure you get the best experience on our website. [Learn more](https://www.transmedics.com)\n\nDeclineAllow cookies\n\n[ Skip to main navigation ](#main-menu)\n\n[ ![Transmedics](/sites/g/files/knoqqb40671/themes/site/nir_pid3225/client/img/TransMedics_Branding.svg) ](https://www.transmedics.com/)\n\nSelect Page\n\n  * [Patients and Families](https://www.transmedics.com/patients-and-families/)\n    * [Organ Care System](https://www.transmedics.com/patients-and-families/)\n    * [OCS Lung](https://www.transmedics.com/ocs-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-liver/)\n    * [Find an OCS Location](https://www.transmedics.com/locate-ocs/)\n  * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [Organ Care System](https://www.transmedics.com/ocs-hcp/)\n    * [OCS Lung](https://www.transmedics.com/ocs-hcp-lung/)\n    * [OCS Heart](https://www.transmedics.com/ocs-hcp-heart/)\n    * [OCS Liver](https://www.transmedics.com/ocs-hcp-liver/)\n  * [Our Company](https://www.transmedics.com/our-company/)\n    * [Our Company](https://www.transmedics.com/our-company/)\n    * [Leadership](https://www.transmedics.com/leadership/)\n    * [Facilities](https://www.transmedics.com/facilities-and-training/)\n    * [Publications](https://www.transmedics.com/publications/)\n    * [Careers](https://www.transmedics.com/careers/)\n  * [Investors](/)\n    * [Overview](/)\n    * [Stock Information](/stock-quote-chart)\n      * [Analyst Coverage](/financial-information/analyst-coverage)\n      * [Stock Quote & Chart](/stock-quote-chart)\n    * [News & Events](/news-releases)\n      * [News Releases](/news-releases)\n      * [Events](/investor-calendar)\n      * [Presentations](/presentations)\n    * [Financial Information](/sec-filings)\n      * [SEC Filings](/sec-filings)\n    * [Corporate Governance](/governance-highlights)\n      * [Governance Highlights](/governance-highlights)\n      * [Management Team](https://www.transmedics.com/leadership/)\n      * [Board of Directors](https://www.transmedics.com/leadership#board-directors-list)\n      * [Committee Composition](/committee-composition)\n    * [ESG](/environmental-social-governance)\n    * [Investor Resources](/investor-faqs)\n      * [Investor FAQs](/investor-faqs)\n      * [Email Alerts](/email-alerts)\n      * [Contact IR](/contact-ir)\n\n\n\n#  Committee Composition \n\n#  Committee Composition \n\n[Audit Committee](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4) | [Compensation Committee](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183) | [Nominating and Corporate Governance Committee](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)  \n---|---|---  \n[ Ed Basile ](/board-member/ed-basile) |  [Audit Committee](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4) |  [Nominating and Corporate Governance Committee](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)  \n[ Thomas Gunderson ](/board-member/thomas-gunderson) |  [Audit Committee](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4) |  [Compensation Committee](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183)  \n[ Ed Kania ](/board-member/ed-kania) |  [Audit Committee](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4)  \n[ Stephanie Lovell ](/board-member/stephanie-lovell) |  [Compensation Committee](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183) |  [Nominating and Corporate Governance Committee](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)  \n[ Merilee Raines ](/board-member/merilee-raines) |  [Audit Committee](/static-files/f4dbe66f-c88d-4a59-b1e4-4b2787bbb0f4) |  [Compensation Committee](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183)  \n[ Jim Tobin ](/board-member/jim-tobin) |  [Nominating and Corporate Governance Committee](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)  \n[ David Weill ](/board-member/david-weill) |  [Compensation Committee](/static-files/edfa55c4-9124-4244-92ee-3261f2afc183) |  [Nominating and Corporate Governance Committee](/static-files/97cce5ca-5884-4b3a-a06a-51ace1943d0a)  \n  \n= Chairperson = Member = Financial Expert = Chairman of the Board\n"
        }
      ]
    }
  ]
}